Andrew Serafin - Dec 2, 2022 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Signature
/s/ Christian Ulrich, Attorney-in-Fact
Stock symbol
HRMY
Transactions as of
Dec 2, 2022
Transactions value $
-$1,972,740
Form type
4
Date filed
12/5/2022, 03:10 PM
Next filing
Jan 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Options Exercise $312K +38K $8.22* 38K Dec 2, 2022 Direct
transaction HRMY Common Stock Sale -$2.23M -37.1K -97.58% $60.12 920 Dec 2, 2022 Direct F1, F2
transaction HRMY Common Stock Sale -$55.9K -920 -100% $60.71 0 Dec 2, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRMY Stock Option Options Exercise $0 -38K -31.22% $0.00 83.7K Dec 2, 2022 Common Stock 38K $8.22 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.67 to $60.66. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.67 to $60.77. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock options vests in five equal annual installments beginning on October 1, 2018.